Abstract
Several oxylipins are potent lipid mediators that regulate diverse aspects of health and disease and whose quantitative analysis by liquid chromatography-mass spectrometry (LC-MS) presents substantial technical challenges. As members of the lipidomics community, we developed technical recommendations to ensure best practices when quantifying oxylipins by LC-MS.
| Original language | English |
|---|---|
| Article number | eadw1245 |
| Journal | Science Signaling |
| Volume | 18 |
| Issue number | 887 |
| DOIs | |
| Publication status | Published - 20 May 2025 |
Funding
The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the Agency for Toxic Substances and Disease Registry. Use of trade names is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention, the Public Health Service, or the US Department of Health and Human Services. We gratefully acknowledge the following funding sources: LIPID MAPS (MRC MR/Y000064/1 to V.B.O.), US National Institutes of Health (R01 GM125944 to F.J.S.; R01 HL132550, P01 HL103455, and R33 HL157069 to B.F.; S10 OD23402 and S10 OD032141 to S.L.G.; U54 NS127758 to B.D.H.; R35 GM139641 to E.A.D.; and R21 AG081823 to G.L.M.), US National Institute of Environmental Health Sciences (Z01 ES025034 to D.Z. and R35 ES030443-01 and P42 ES004699 to B.D.H.), US Department of Agriculture (2032-51530-025-00D to J.W.N.), Medical Research Council (MR/Y000064/1 to V.B.O., MC_UU_00028/4 to M.P.M., and BB/W018322/1 to R.D.), European Union (ERC Adv grant no. 101095860 to M.H., CA19105 to M.F. and R.D., and 847419 to C.S.), Wellcome Trust (220257/Z/20/Z to M.P.M.), German Research Foundation (SCHE 1801 to N.H.S.; FE 1236/5-1 and FE 1236/8-1 to M.F. and SFB 1039/Z01 to R.G. and D.T.), German Federal Ministry of Education and Research (BMBF 031L0315A, DEEP_HCC and 01EJ2205A, and FERROPath to M.F.), São Paulo Research Foundation (FAPESP #2013/07937-8 to S.M.), Carlos III Health Institute (CP21II/00003 to J.K.), Ministerio de Ciencia, Innovación y Universidades/Agencia Estatal de Investigación/10.13039/501100011033 and the European Union NextGenerationEU/Plan de Recuperación, Transformación, y Resiliencia (JDC2022-049354-I to A.S.-I.), Natural Sciences and Engineering Research Council of Canada (RGPIN-2021-03777 to N.F.), the Portuguese Centre for the Environment and Marine Studies CESAM (UIDB/50017/2020, UIDP/50017/2020, and LA/P/0094/2020 to R.D.), and the Alzheimer's Association (AARGD-22-926459 to I.D.). Acknowledgments: The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the centers for Disease control and Prevention or the agency for Toxic Substances and Disease Registry. use of trade names is for identification only and does not imply endorsement by the centers for Disease control and Prevention, the Public Health Service, or the uS Department of Health and Human Services. Funding: We gratefully acknowledge the following funding sources: liPiD MaPS (MRc MR/Y000064/1 to V.B.o.), uS national institutes of Health (R01 gM125944 to F.J.S.; R01 Hl132550, P01 Hl103455, and R33 Hl157069 to B.F.; S10 oD23402 and S10 oD032141 to S.l.g.; u54 nS127758 to B.D.H.; R35 gM139641 to e.a.D.; and R21 ag081823 to g.l.M.), uS national institute of environmental Health Sciences (Z01 eS025034 to D.Z. and R35 eS030443-01 and P42 eS004699 to B.D.H.), uS Department of agriculture (2032-51530-025-00D to J.W.n.), Medical Research council (MR/ Y000064/1 to V.B.o., Mc_uu_00028/4 to M.P.M., and BB/ W018322/1 to R.D.), european union (eRc adv grant no. 101095860 to M.H., ca19105 to M.F. and R.D., and 847419 to c.S.), Wellcome Trust (220257/Z/20/Z to M.P.M.), german Research Foundation (ScHe 1801 to n.H.S.; Fe 1236/5-1 and Fe 1236/8-1 to M.F. and SFB 1039/Z01 to R.g. and D.T.), german Federal Ministry of education and Research (BMBF 031l0315a, DeeP_Hcc and 01eJ2205a, and FeRRoPath to M.F.), São Paulo Research Foundation (FaPeSP #2013/07937-8 to S.M.), carlos iii Health institute (cP21ii/00003 to J.K.), Ministerio de ciencia, innovación y universidades/agencia estatal de investigación/10.13039/501100011033 and the european union nextgenerationeu/Plan de Recuperación, Transformación, y Resiliencia (JDc2022-049354-i to a.S.-i.), natural Sciences and engineering Research council of canada (RgPin-2021-03777 to n.F.), the Portuguese centre for the environment and Marine Studies ceSaM (uiDB/50017/2020, uiDP/50017/2020, and la/P/0094/2020 to R.D.), and the alzheimer’s association (aaRgD-22-926459 to i.D.). Competing interests: V.B.o. is a consultant for Metasight. B.D.H. is a founder of eicosis Human Health with a potential pharmaceutical in clinical trials whose action depends on altering the profile of inflammatory lipids. K.M. is president and ceo of cayman chemical and a supplier of lipid standards. M.g. is a cofounder of the company enfanos llc. B.F. acknowledges a financial interest in creegh Pharmaceuticals, inc. e.a. Dennis is a cofounder of liponexus, inc. B.F. acknowledges an interest in creegh Pharmaceuticals, inc. K.e. is the owner of lipidomics consulting ltd. n.H.S., K.e., g.l.M., M.a.g., H.W.V., c.e.W., and V.B.o. are members of the international lipidomics Society oxylipin interest group.
| Funders | Funder number |
|---|---|
| Bundesministerium für Bildung und Forschung | 01eJ2205a, 031l0315a |
| Fundação de Amparo à Pesquisa do Estado de São Paulo | 2013/07937-8 |
| University of Oxford | Z01 eS025034, ES030443-01, P42 eS004699 |
| NextGenerationEU | JDC2022-049354-I |
| Wellcome Trust | 220257/Z/20/Z |
| Medical Research Council | BB/ W018322/1, MC_UU_00028/4, MR/Y000064/1 |
| Natural Sciences and Engineering Research Council of Canada | RGPIN-2021-03777 |
| U.S. Department of Agriculture | 2032-51530-025-00D |
| Ministerio de Ciencia, Innovación y Universidades/Agencia Estatal de Investigación/10 | .13039/501100011033 |
| Instituto de Salud Carlos III | cP21ii/00003 |
| European Research Council | CA19105, 101095860 |
| Deutsche Forschungsgemeinschaft | ScHe 1801, Fe 1236/8-1, FE 1236/5-1, SFB 1039/Z01 |
| National Institutes of Health | P01 Hl103455, R21 ag081823, U54 NS127758, S10 oD23402, S10 oD032141, R01 gM125944, R35 GM139641, R01 Hl132550, R33 Hl157069 |
| Portuguese Centre for the Environment and Marine Studies CESAM | LA/P/0094/2020, UIDB/50017/2020, UIDP/50017/2020 |
| National Alzheimer's Association | AARGD-22-926459 |
Keywords
- Oxylipins/analysis
- Chromatography, Liquid/methods
- Mass Spectrometry/methods
- Humans
- Lipidomics/methods
- Animals
- Liquid Chromatography-Mass Spectrometry
Fingerprint
Dive into the research topics of 'Technical recommendations for analyzing oxylipins by liquid chromatography-mass spectrometry'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS